HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

503.398

-20.475-3.91%

Number of Gainers:8

Number of Losers:24

Number of Flat:1

PE:- -

High:523.582

Open:523.582

Low:498.297

Close:523.873

Volume:119.87M

Turnover:3.20B

Market Cap:322.68B

Float Cap:286.07B

Loading ...

Venus Medtech Hangzhou Says Six-Month Revenue Rmb135.5 Million

China's United Laboratories Half-Year Profit Drops 82%

HEARTCARE-B Reports Strong 2026 Interim Results: Revenue Up 56.9% to RMB290 Million, Adjusted Net Profit Surges 105.9%

Jhbp Cy - Chairman and CEO NI Xin to Buy Shares up to USD 1 Mln from Aug 31, 2026

THOMSON REUTERS

SinoMab BioScience Ltd - Hy Loss Rmb127.4 Mln

THOMSON REUTERS

SinoMab FY26 H1 Loss Widens to RMB 127.4 Million; Funding Available Drops to RMB 196.5 Million

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Venus MedTech FY26 H1 Net Loss Widens 41.9% to RMB 191.31 Million; Revenue Falls 27.6% to RMB 135.5 Million

Venus Medtech Hangzhou - Six-Month Revenue Rmb135.5 Mln

THOMSON REUTERS

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Brii Biosciences Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy

THOMSON REUTERS

Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million

Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million

THOMSON REUTERS

China's Hongcheng Environmental Technology HY Revenue Rises on Higher Sulphuric Acid Prices

Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each

CStone Plans First Wave of Global Phase III Trials for Cs2009 by End-2026

CStone Says Pralsetinib Sales Volume Jumps Nearly 500% After China NRDL Listing

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":503.39795,"timestamp":1788163726135,"preClose":523.8731,"halted":0,"volume":119868273,"delay":0,"changeRate":-0.039084,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-20.475159,"latestTime":"08-31 16:00:00","open":523.582,"high":523.582,"low":498.29733,"amount":3203299214.5,"amplitude":0.048265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":3.909696,"peRate":137.956161,"turnoverRate":0.003654,"increases":8,"decrements":24,"flats":1,"marketCap":322680201168,"floatMarketCap":286067329608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":523.582,"amplitude":0.048265,"preClose":523.8731,"low":498.29733,"pbRate":"3.909696","latestPrice":503.39795,"volume":119868273,"delay":0,"open":523.582,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":496.742,"twentyDayClose":467.18,"sixtyDayClose":475.465,"secType":"PLATE","market":"HK","turnoverRate":0.003654,"peRate":137.956161,"marketCap":322680201168,"floatMarketCap":286067329608,"timestamp":1788163726135,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663004431","title":"Venus Medtech Hangzhou Says Six-Month Revenue Rmb135.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004431","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004431?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:21","pubTimestamp":1788189709,"startTime":"0","endTime":"0","summary":"BRIEF-Venus Medtech Hangzhou Says Six-Month Revenue Rmb135.5 MillionAug 31 (Reuters)-Venus Medtech (Hangzhou) Inc2500.HK:SIX-MONTH REVENUE RMB135.5 MILLIONFurther company coverage:2500.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1100","02500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004932","title":"China's United Laboratories Half-Year Profit Drops 82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004932?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:11","pubTimestamp":1788189105,"startTime":"0","endTime":"0","summary":"China's United Laboratories half-year profit drops 82%OverviewChina pharmaceutical maker's half-year revenue fell 18% yr/yrNet income attributable to owners dropped 82% yr/yrCompany did not declare in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03933","00950","01672","01228","BK1515","IE00B3M56506.USD","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171415138","title":"HEARTCARE-B Reports Strong 2026 Interim Results: Revenue Up 56.9% to RMB290 Million, Adjusted Net Profit Surges 105.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171415138","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171415138?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:48","pubTimestamp":1788187703,"startTime":"0","endTime":"0","summary":"HEARTCARE-B (06609) released its interim results for the first half of 2026 on August 31. During the period, the company generated revenue of RMB290 million, marking a 56.9% year-on-year increase....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06609","BK1100","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663119001","title":"Jhbp Cy - Chairman and CEO NI Xin to Buy Shares up to USD 1 Mln from Aug 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663119001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663119001?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:41","pubTimestamp":1788187276,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","06998","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663001896","title":"SinoMab BioScience Ltd - Hy Loss Rmb127.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663001896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663001896?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:27","pubTimestamp":1788186426,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663001857","title":"SinoMab FY26 H1 Loss Widens to RMB 127.4 Million; Funding Available Drops to RMB 196.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663001857","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663001857?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:25","pubTimestamp":1788186341,"startTime":"0","endTime":"0","summary":"SinoMab FY26 H1 loss widens to RMB 127.4 million; funding available drops to RMB 196.5 millionSinoMab posted a net loss of RMB 127.4 million for the six months ended June 30, 2026, versus RMB 49.8 mil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5rZnp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663966006","title":"China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2663966006","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663966006?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:31","pubTimestamp":1788183111,"startTime":"0","endTime":"0","summary":"China's Ascletis Pharma H1 net loss widens on higher R&D costsOverviewChina biopharma developer's interim net loss widened 263% yr/yr to RMB319.7 mlnTotal income for the period fell 49% yr/yrR&D expen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","BK1515","BK4585","01672","01228","BK4535","BK1574","BK1161","BNTX","BK4568","BK4551","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663066930","title":"Venus MedTech FY26 H1 Net Loss Widens 41.9% to RMB 191.31 Million; Revenue Falls 27.6% to RMB 135.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663066930","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663066930?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:30","pubTimestamp":1788183057,"startTime":"0","endTime":"0","summary":"Venus MedTech FY26 H1 net loss widens 41.9% to RMB 191.31 million; revenue falls 27.6% to RMB 135.5 millionVenus Medtech posted revenue of RMB 135.5 million, down 27.6% year over year, for the six mon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL8rnpL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02500","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006653","title":"Venus Medtech Hangzhou - Six-Month Revenue Rmb135.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006653?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:30","pubTimestamp":1788183044,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02500","BK1100","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123847780","title":"Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1123847780","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123847780?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:28","pubTimestamp":1788182898,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has unveiled its financial results for the six months ended June 30, 2026. The company recorded total revenue of RMB 52.979 million, representing a year-on-year decrease of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1515","BK1574","BK1191","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006385","title":"Brii Biosciences Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006385","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006385?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:21","pubTimestamp":1788182514,"startTime":"0","endTime":"0","summary":"Brii Biosciences files HKEX next-day disclosure return on share repurchase for cancellationBrii Biosciences repurchased 20,000 ordinary shares on Aug. 31 for treasury, with no shares cancelled.Buyback","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3NWc5r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1574","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005700","title":"Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663005700?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:16","pubTimestamp":1788182176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663100571","title":"Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663100571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663100571?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182109,"startTime":"0","endTime":"0","summary":"Ascletis Pharma FY26 H1 net loss more than doubled to RMB 319.67 million; total income falls 48.9% to RMB 52.98 millionAscletis Pharma posted a net loss of RMB 319.67 million, more than tripling year-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7N2P2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800579","title":"Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800579?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nPLX1DNJ6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663053100","title":"China's Hongcheng Environmental Technology HY Revenue Rises on Higher Sulphuric Acid Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2663053100","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663053100?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:59","pubTimestamp":1788181171,"startTime":"0","endTime":"0","summary":"China's Hongcheng Environmental Technology HY revenue rises on higher sulphuric acid pricesOverviewChina environmental solutions provider's interim revenue rose 40% yr/yr for six months ended JuneGros","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06699","BK1593","BK1574","02265","BK1100","BK1140","BK1587","06609","BK1583","02297"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003766","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003766","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003766?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:46","pubTimestamp":1788180401,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return reporting share repurchase at HKD 8.9 eachAlphamab Oncology repurchased 110,000 ordinary shares on HKEX on Aug. 31, 2026 for treasury.Buyback pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3kwvC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003801","title":"CStone Plans First Wave of Global Phase III Trials for Cs2009 by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003801","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003801?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788179038,"startTime":"0","endTime":"0","summary":"CStone plans first wave of global Phase III trials for CS2009 by end-2026CStone highlighted stronger mid-stage clinical results for lead cancer drug CS2009, supporting plans to start global Phase III ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLpMLV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663038020","title":"CStone Says Pralsetinib Sales Volume Jumps Nearly 500% After China NRDL Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2663038020","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663038020?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788179035,"startTime":"0","endTime":"0","summary":"CStone says pralsetinib sales volume jumps nearly 500% after China NRDL listingCStone reported 2026 interim results, highlighting CS2009 Phase I/II updates through August with sustained safety and dee","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL1XJFFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","IE00BFXG0V08.USD","BK1161","LU1223082519.USD","IE00B5TLWC47.USD","IND","BK1574","BK4211","LU2211817866.USD","LU1093756168.USD","CDE","BK4533","BK4585","LU2413666426.HKD","LU1223082196.USD","BK4567","BK4548","LU2487616109.SGD","MTD","LU0053666078.USD","XME","SIL","LU1223083913.SGD","BK4017","SGDM","BK4107","PFS","LU0347712357.USD","BK4588","ORR","LU1093756325.SGD","IE00BYQQ9H92.USD","02616","LU1721428933.USD","L","BK4121","LU2413666699.HKD","GDXJ","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008151","title":"Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008151","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008151?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:04","pubTimestamp":1788177853,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-202.The trial is studying the drug for the treatment of dry eye disease in China, according to a Monday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1574","LENZ","01477","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":1,"totalSize":375,"code":"91000000","status":"200"}]}}